TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Preferences regarding physical activity counseling and interventions
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Frequency of spanking
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Phacoemulsification energy required
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Duration of ultrasound time required
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Phacoemulsification power required
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: inflammation in airway tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: remodelling in airway tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Temperature of mother
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hospital admission within 7 days
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: change of the blood glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Saliva collection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in number of urge related incontinence episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Maximum Serum Concentration (Cmax) of Tabalumab After Loading Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration Time Curve From Time 0 to 14 Days [AUC(0-14)]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Talocrural joint dorsiflexion ROM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence and degree of neutropenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Recovery time of neutropenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: hemoglobin and/or red blood cell (RBC) transfusion-dependence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in hemodynamic state
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time for definitive soft tissue coverage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Humoral rejection diagnosed by biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in practices of consumption of psychoactive substances
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Drug Concentration-time Curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Annualized Number of Total Bleeds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: < 5% Marrow Blast
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: no Circulating Peripheral Blasts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Neutrophil Count of > 1 x 10^9/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percent of pregnant and postpartum women tested for HIV
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Degree of improvement in Erythematotelangiectatic Rosacea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Fecal inflammatory marker
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in EEG frontal alpha asymmetry
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in behavioral approach-avoidance
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in skin conductance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EDSS changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Relapse rate of MS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PASAT test
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Nine hole PEG test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: timed ten meter walking
Endpoint domain: Physiological/clinical
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Reflective Total Nasal Symptom Score (rTNSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Treatment Related Adverse Events (Safety)
Endpoint domain: Adverse events/effects
Primary endpoint: Respiratory quotient (RQ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with dose limiting toxicities (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Late revascularization therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Liver and cardiovascular-related mortality
Endpoint domain: Mortality/survival
Primary endpoint: description of AE profile
Endpoint domain: Adverse events/effects
Primary endpoint: IDEA-033 plasma levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: visual assessment of skin at target area(s)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: physical exam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy (Response Rate) of Vorinostat Combined With RICE Chemotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and Toxicity According to CTCAE v3.0
Endpoint domain: Adverse events/effects
Primary endpoint: Ability to Proceed to Peripheral Blood Stem Cell Collection Following Treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: 6-min-walk distance increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reward-related brain function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Duration of on time without dyskinesias or with non-bothersome dyskinesias
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Postoperative respiratory failure or ARDS or requiring tracheal intubation
Endpoint domain: Adverse events/effects
Primary endpoint: Gut microbiota composition using 16S rRNA sequencing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gut microbiota composition using rectosigmoid biopsy tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of Elevated TCD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Change in Primary Stroke Risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improvement in Liver Iron Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: incidence of chromosome abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Presence/absence of urinary incontinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Caregivers' Competence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Caregivers' Preparedness
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patients' emergency service visiting
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change from baseline quality of life at 12 weeks: King's Brief Interstitial Lung Disease Questionnaire (K-BILD)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change from baseline quality of life at 12 weeks: Hospital Anxiety and Depression Scale (HADS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Moderate-Vigorous Physical Activity (MVPA) in 10 Min Bouts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-time Curve (AUCτ, ss, Combined)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Indoor Tanning Sessions in the Last 30 Days
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of Outdoor Tanning Sessions in the Last 30 Days
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of Participants With Antibody Titers ≥1:4 and ≥1:8 Measured by hSBA Following Vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants With Vaccine Seroresponse Measured by hSBA Following Vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric Mean Titers (GMTs) of Antibodies Against Meningococcal Serogroups Measured by hSBA Following Vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change From Baseline in Hamilton Rating Scale for Depression-17 (HDRS17) Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Hamilton Rating Scale for Depression-17 (HDRS17) Sleep Item-Adjusted Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Hamilton Rating Scale for Depression-17 (HDRS17) Anxiety/Somatization Factor Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in 6 Item Subscale From HDRS17 (HAM-D6) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Impairment of glucose tolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Shared Decision Making (SDM) Process Scale Score
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: total IVIg dose (g/Kg)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Cognitive Scaled Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gross Motor Scaled Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of Warfarin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tmax of Warfarin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-t of Warfarin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of successful donor engraftment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Validation of gadolinium free fibrosis imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of viruses detected
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Rate of Implant Failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Binge drinking episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 1 year cumulative incidence overall survival
Endpoint domain: Mortality/survival
Primary endpoint: epileptiform EEG discharges
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Antibody binding to SARS-CoV-2 proteins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Presence of SARS-CoV-2 peptides in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Degree of oxidative damage to lipids
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Phenylalanine Requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Disease Activity Score 28 (DAS28) at Month 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Disease Activity Index (CDAI) Score at Month 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with drop in HPV specific viral load
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in food allergy-specific quality of life score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: overall response rate (dose expansion)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Most efficacious dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ability to distinguish between receiving placebo or study drug
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Absolute BNP change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in HAART adherence level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Suppression of periodic breathing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Daily frequency and severity of moderate to severe vasomotor symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Receipt of Standard Therapy at Any Point During the 7-day Treatment Period
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Adherence to Iron Replacement Therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Death among children 1-36 months of age
Endpoint domain: Mortality/survival
Primary endpoint: exam quality
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patients That Are Free From Patency-related Intervention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of impulsive choices (Food Choice Questionnaire)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of impulsive choices (Monetary Choice Questionnaire)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change-from-baseline Mean Effect of P03277 on QT Interval (∆QTcF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: ondansetron serum level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in pain score
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Number of Participants With Abemaciclib Dose Limiting Toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Progression Free Survival (PFS) Rate at 3 Months
Endpoint domain: Mortality/survival
Primary endpoint: Changes in periocular skin sensation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic accuracy of diffusion tensor MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of Participants Who Experience One or More Treatment-related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Invasively Measured Pulmonary Artery Pressures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximum Concentration of DS-3201a (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration-time curve from time zero to time of last measurable concentration of DS-3201a (AUClast)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration-time curve up to infinity of DS-3201a (AUCinf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Left Ventricular (LV) Mass Over Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants With Any On-treatment Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Duration of Use of Arterial Cannula
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Self-reported anthropometric outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerance of modified vaccinia virus ankara vaccine
Endpoint domain: Adverse events/effects
Primary endpoint: Total urinary concentration of amikacin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: low optical ratio (LOR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Score on the 17-item HRSD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in impedance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Patients Without Remaining Live Cysts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: T-stage in left sided colonic cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Agreement between sonographic and clinical diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Length of stay at the emergency department
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: ADHD-IV Rating Scale (ADHD-RS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incremental area under the curve for plasma glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Hospitalization due to cardiac causes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Lead-related complications
Endpoint domain: Adverse events/effects
Primary endpoint: Ventricular premature beats
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in the proportion of people adherent to treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in laboratory data
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Renal Response to Acthar Gel
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Cognitive performance measured by the Stroop test
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Cognitive performance measured by the Trails B test
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Clinical outcome of the Sigma knee
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma concentrations of gold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tumor area in endoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Local Disease Control Rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Covid-19 Infection
Endpoint domain: Mortality/survival
Primary endpoint: Change in Diet Groups Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Medical adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Emergence of antimicrobial resistance or isolation of a potential pathogen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of Participants With Gagging Reaction
Endpoint domain: Adverse events/effects
Primary endpoint: Presence of new brain lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Rejection Reversal or Recurrent Rejection
Endpoint domain: Adverse events/effects
Primary endpoint: Costs of health resources with DBS
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Costs of health resources with vertebral fusions
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Improvement of disability measured by Oswestry Disability Index (ODI)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: AUC non-HDL-cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: change in gesture performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of any immediate reactions after vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of any unsolicited adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of serious adverse events during the study
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence rate of Oxaliplatin-induced Peripheral Neuropathy
Endpoint domain: Adverse events/effects
Primary endpoint: Quality of brachytherapy implants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Baseline-adjusted Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve (AUC 0-6)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mean and median time to complete the entire geriatric assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Geriatric Assessments for which all three items are completed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diet Quality of Household Food Purchases
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes